Related Experiment Videos
Ribavirin aerosol for acute bronchiolitis
Insights
This randomized trial found that aerosolized ribavirin improved cough and respiratory rates in infants with bronchiolitis. The antiviral treatment was well-tolerated and showed promising results for managing this common respiratory illness.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Bronchiolitis is a common viral respiratory infection in infants.
- Respiratory Syncytial Virus (RSV) is the primary causative agent.
- Current treatments are largely supportive.
Purpose of the Study:
- To evaluate the efficacy and safety of aerosolized ribavirin in treating infantile bronchiolitis.
- To assess the impact of ribavirin on clinical outcomes and viral clearance.
Main Methods:
- A randomized, double-blind, placebo-controlled trial.
- 26 infants with clinically diagnosed bronchiolitis received either nebulized ribavirin or normal saline aerosol for at least three days.
- Clinical variables and viral shedding were monitored.
Main Results:
- Ribavirin treatment showed trends favoring faster improvement in cough, crepitations, respiratory rate, and heart rate.
- Significant reductions in chest recession were observed in infants with confirmed RSV.
- No difference in viral clearance rates was noted between groups.
- Treatment was well-tolerated with no significant adverse effects.
Conclusions:
- Nebulized ribavirin may be a beneficial treatment option for certain cases of infantile bronchiolitis.
- Further research is warranted to confirm its role in managing this condition.
Abstract:
A randomised double blind placebo controlled trial of treatment with an aerosolised antiviral agent, ribavirin, was conducted in 26 infants with clinically diagnosed bronchiolitis. Nebulised ribavirin (14 infants) or normal saline aerosol (12 infants) was given for 18 hours a day for at least three days. Respiratory syncytial virus was identified in nasal secretions from 20 cases (10 from both groups). Trends in seven out of eight clinical variables favoured active treatment. Ribavirin aerosol was associated with significantly faster improvement in cough and crepitations and more rapid rate of fall in respiratory and heart rates. In the 20 infants from whose nasal secretions respiratory syncytial virus was identified most variables favoured treatment with ribavirin, with significant reduction in chest recession. No difference was found in the rate of clearance of respiratory syncytial virus. The treatment was well tolerated as judged clinically and from the results of haematological and biochemical studies. The study suggests nebulised ribavirin may have a place in the treatment of some cases of bronchiolitis.